Executive Order 14293—Regulatory Relief To Promote Domestic Production of Critical Medicines

Executive Order 14293, titled "Regulatory Relief To Promote Domestic Production of Critical Medicines," directs the Secretary of Health and Human Services, through the FDA Commissioner, to review and streamline regulations for domestic pharmaceutical manufacturing. This includes taking steps to eliminate duplicative or unnecessary requirements, maximize the timeliness and predictability of agency review, and accelerate the development of new and expanded manufacturing facilities for pharmaceutical products and their ingredients within the United States. This action primarily affects companies involved in pharmaceutical manufacturing in the U.S. and aims to benefit American patients.

The President stated that this order is intended to address critical barriers, such as the long time it takes to build pharmaceutical manufacturing facilities—estimated at 5 to 10 years—and frequent unannounced FDA inspections of domestic manufacturers. The goal is to establish a domestic, resilient, and affordable pharmaceutical supply chain for American patients and to make the United States more competitive in manufacturing safe and effective pharmaceutical products, which is considered important from a national security standpoint.

Executive orders are a long-established exercise of presidential power, used by every President since George Washington and grounded in Article II of the Constitution. However, executive orders cannot create new law or contradict existing federal statutes, and courts can review them to ensure they conform with the Constitution and federal law.

AI-generated summary for educational purposes